Delta4, a digital drug discovery company, identified a potential therapeutic option for Focal Segmental Glomerulosclerosis (FSGS) using their Hyper-C AI […]
Author: Kurt Herpel
Understanding the Drug Discovery Pipeline: From the Lab to the Patient
The world of pharmaceuticals is complex and layered. At the heart of this realm is the drug discovery pipeline, a […]
The Transformative Role of AI in Pharma – An Exploration
What is Artificial Intelligence? Artificial Intelligence (AI) is a field of computer science that aims to mimic human intelligence, enabling […]
Delta4 CEO Kurt Herpel Featured in Insightscare Magazine: A Vision for the Future of Drug Discovery
We are incredibly proud to share that our esteemed CEO, Kurt Herpel, has recently been profiled in Insightscare Magazine. In […]
Delta4 Announces Prof. Doron Lancet To Join Scientific Advisory Board
VIENNA, Austria, March 6th, 2023 — Delta4, a digital drug discovery company focusing on the identification of new indications for […]
4P-Pharma And Delta4 Join Forces To Find And Develop Treatments For A Rare Autoimmune Chronic Liver Disease
Paris (France) and Vienna (Austria), 31st May 2022 – 4P-Pharma, a French clinical-stage biotechnology company, and Delta4, an Austrian digital […]
Delta4, in preparation for the first clinical study, focused on FSGS
Focal Segmental Glomerulosclerosis (FSGS) is a devastating clinical condition with defined glomerular histopathology and yet a multifaceted pathophysiological, histological, and […]
Delta4 at BIO-EUROPE 2021
From October 25-28 Delta4 attended the (virtual) BIO-EUROPE conference, the largest partnering event in Europe dedicated to the global biotechnology […]
Delta4 Announces Dr. Hans Lehrach to Join Scientific Advisory Board
VIENNA, Austria, September 27th, 2021 — Delta4, a digital drug discovery company focusing on the identification of new indications for […]
FSGS and COVID-19 programs ready for Phase II studies
We are proud to announce further progress in our current drug discovery and development programs. In late 2020, Delta4 filed […]